Advanced search
Publication Cover
Expert Review of Vaccines Volume 13, 2014 - Issue 1
Submit an article Journal homepage
406
Views
11
CrossRef citations to date
0
Altmetric
Reviews

Therapeutic cancer vaccines: a long and winding road to success

Constantin N BaxevanisSt. Savas Cancer Hospital, Cancer Immunology and Immunotherapy Center, 171 Alexandras Avenue, 11522 Athens, GreeceCorrespondence[email protected]
,
Michael PapamichailSt. Savas Cancer Hospital, Cancer Immunology and Immunotherapy Center, 171 Alexandras Avenue, 11522 Athens, Greece
&
Sonia A PerezSt. Savas Cancer Hospital, Cancer Immunology and Immunotherapy Center, 171 Alexandras Avenue, 11522 Athens, Greece
Pages 131-144 | Published online: 10 Jan 2014

References

  • Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004).
  • Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J. Biomed. Biotechnol. 2010, 596432 (2010).
  • Mellman I, Coukos G, DranoffG. Cancer immunotherapy comes of age. Nature 480(7378), 480–489 (2011).
  • Perez SA, von Hofe E, KallinterisNLet al. A new era in anticancer peptide vaccines. Cancer 116(9), 2071–2080 (2010).
  • PawelecG. Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol. Immunother. 53(3), 262–274 (2004).
  • Umansky V, Sevko A. Melanoma-induced immunosuppression and its neutralization. Semin. Cancer Biol. 22(4), 319–326 (2012).
  • Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg. Oncol. Clin. N. Am. 16(4), 755–774 (2007).
  • Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol. Immunother. 61(2), 249–254 (2012).
  • Ferris RL, Whiteside TL. Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin. Cancer Res. 12(13), 3890–3895 (2006).
  • Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, KroemerG. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 71(17), 5601–5605 (2011).
  • Schietinger A, Philip M, Liu RB, Schreiber K, SchreiberH. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J. Exp. Med. 207(11), 2469–2477 (2010).
  • Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin. Biol. Ther. 10(7), 1019–1035 (2010).
  • SolimanH. Developing an effective breast cancer vaccine. Cancer Control 17(3), 183–190 (2010).
  • Yamada A, Sasada T, Noguchi M, ItohK. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 104(1), 15–21 (2013).
  • Boon T, Coulie PG Van den Eynde BJ, vander Bruggen P. HumanT cell responses against melanoma. Annu. Rev. Immunol. 24, 175–208 (2006).
  • Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv. Surg. 45, 341–360 (2011).
  • Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin. Cancer Res. 17(12), 3884–3891 (2011).
  • Kaufman HL, Kim-Schulze S, MansonK et al. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J. Transl. Med. 5, 60 (2007).
  • Goldman B. DeFrancesco L. The cancer vaccine roller coaster. Nat. Biotechnol. 27(2), 129–139 (2009).
  • Flammiger A, Weisbach L, HulandH et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur. J. Cancer 49(6), 1273–1279 (2013).
  • Curiel TJ, Coukos G, ZouLet al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942–949 (2004).
  • Gulley JL, Arlen PM, MadanRAet al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59(5), 663–674 (2010).
  • Fujimura T, Kambayashi Y, AibaS. Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth. Oncoimmunology 1(8), 1433–1434 (2012).
  • Fujimura T, Ring S, Umansky V, Mahnke K, Enk AH. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J. Invest. Dermatol. 132(4), 1239–1246 (2012).
  • Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol. Immunother. 61(2), 283–288 (2012).
  • SchlomJ. Therapeutic cancer vaccines: current status and moving forward. J. Natl Cancer Inst. 104(8), 599–613 (2012).
  • Kenter GG, Welters MJ, ValentijnARet al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361(19), 1838–1847 (2009).
  • Walter S, Weinschenk T, StenzlAet al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18(8), 1254–1261 (2012).
  • Kruit WH, Suciu S, DrenoBet al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J. Clin. Oncol. 31(19), 2413–2420 (2013).
  • Vansteenkiste J, Zielinski M, LinderA et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J. Clin. Oncol. 31(19), 2396–2403 (2013).
  • Ulloa-Montoya F, Louahed J, DizierBet al. Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy. J. Clin. Oncol. 31(19), 2388–2395 (2013).
  • Kantoff PW, Higano CS, ShoreNDet al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
  • Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17(11), 3520–3526 (2011).
  • Figlin RA, Amin A, DudekA et al.; AGS-003-006 Study Group. Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. (Meeting Abstracts) 30, 348 (2012).
  • Gulley JL, Arlen PM, TsangKYet al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 14(10), 3060–3069 (2008).
  • Kantoff PW, Schuetz TJ BlumensteinBAet al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099–1105 (2010).
  • Mohebtash M, Tsang KY, MadanRAet al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 17(22), 7164–7173 (2011).
  • Baxevanis CN. Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm. Expert Rev. Vaccines 11(3), 275–277 (2012).
  • Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA. Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2(2), 213–226 (2010).
  • Sears AK, Perez SA CliftonGTet al. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin. Biol. Ther. 11(11), 1543–1550 (2011).
  • Mittendorf EA, Perez SA, Hale DFet al. Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer. J. Clin. Oncol. 30(Suppl. 27), Abstract 109 (2012).
  • Perez SA, Kallinteris NL, Bisias S et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin. Cancer Res. 16(13), 3495–3506 (2010).
  • Perez SA, Anastasopoulou E, TzonisPet al. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment update on a phase I trial. Cancer Immunol. Immunother. 62, 1599–1608 (2013).
  • Zitvogel L, Apetoh L, Ghiringhelli F, KroemerG. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59–73 (2008).
  • Baxevanis CN, Perez SA. PapamichailM. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother. 58(3), 317–324 (2009).
  • Petrylak D. Defining the optimal role of immunotherapy and chemotherapy: Advanced prostate cancer patients who receive sipuleucel-T (Provenge) followed by docetaxel derive greatest survival benefit. Presented at: Chemotherapy Symposium 14th Annual Meeting. New York, NY, USA, 8–11 November 2006.
  • Arlen PM, Gulley JL, Parker C et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12(4), 1260–1269 (2006).
  • Antonia SJ, Mirza N, FrickeIet al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12(3 Pt 1), 878–887 (2006).
  • Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10(16), 5316–5326 (2004).
  • VansteenkisteJ ZM, Linder, J.Dahabre, E.Esteban, W.Malinowski, J.Jassem, B.Passlick, F. Lehmann, and BrichardV. G. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts). 25(Suppl. 18), 7554 (2007).
  • Schuster SJ, Neelapu SS, Santos CF, Popa-McKiverMA, McCord AM, Kwak LW Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma? J. Clin. Oncol. 29(36), 4845–4846 (2011).
  • Butts C, Murray N, MaksymiukAet al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23(27), 6674–6681 (2005).
  • Butts C, Maksymiuk A, GossGet al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1–01 J. Thorac. Oncol. 2(8), S332–S333 (2007).
  • Butts CA, Socinski MA, Mitchell P et al. START: a phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J. Clin. Oncol. (Meeting Abstracts). 31(Suppl. 15), 7500 (2013).
  • Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722–4729 (2010).
  • Melero I, Grimaldi AM, Perez-GraciaJL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res. 19(5), 997–1008 (2013).
  • Hodi FS, O'DaySJ, McDermottDFet al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
  • Madan RA, Mohebtash M, ArlenPMet al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13(5), 501–508 (2012).
  • Nishimura H, Okazaki T, TanakaYet al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291(5502), 319–322 (2001).
  • Blank C, Brown I, PetersonACet al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 64(3), 1140–1145 (2004).
  • Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, MinatoN. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293–12297 (2002).
  • Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167–3175 (2010).
  • Kline J, Gajewski TF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr. Opin. Investig. Drugs 11(12), 1354–1359 (2010).
  • Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leuko. Biol. 94(1), 41–53 (2013).
  • Hamid O, Robert C, DaudAet al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134–144 (2013).
  • WolchokJ. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann. Oncol. 23(Suppl. 8), viii15–21 (2012).
  • Farsaci B, Sabzevari H, HigginsJPet al. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int. J. Cancer 127(7), 1603–1613 (2010).
  • Farsaci B, Higgins JP, Hodge JW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int. J. Cancer 130(8), 1948–1959 (2012).
  • Boni A, Cogdill AP, Dang P et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70(13), 5213–5219 (2010).
  • Araki K, Turner AP, Shaffer VO et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460(7251), 108–112 (2009).
  • Ohtani M, Nagai S, KondoSet al. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood 112(3), 635–643 (2008).
  • Bilusic M, Gulley JL. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol. Immunother. 61(1), 109–117 (2012).
  • Small EJ, Fratesi P, ReeseDMet al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18(23), 3894–3903 (2000).
  • Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670–3679 (2009).
  • Holmes JP, Clifton GT, Patil R et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 117(3), 463–471 (2011).
  • Mazanet R SM, Ramadan D, Lavin PT. Completed SN33 Trial: 60 month follow-up of Early Stage Node Positive HER2 Negative patients with NeuVax™ (E75) and sargramostim. Cancer Res. 72(24 Suppl. 3), P5-18-07 (2012).
  • Mittendorf EA, Clifton GT, Holmes JP et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 118(10), 2594–2602 (2012).
  • Butterfield LH, Palucka AK, Britten CM et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin. Cancer Res. 17(10), 3064–3076 (2011).
  • Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol. Immunother. 60(3), 433–442 (2011).
  • Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388–1397 (2010).
  • Bindea G, Mlecnik B, Fridman WH, GalonJ. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin. Immunopathol. 33(4), 335–340 (2011).
  • Rubio V, Stuge TB, Singh N et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat. Med. 9(11), 1377–1382 (2003).
  • Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. 170(5), 2523–2530 (2003).
  • Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin. Oncol. 39(3), 296–304 (2012).
  • Cavacini LA, Duval M, Eder JP, Posner MR. Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen. Clin. Cancer Res. 8(2), 368–373 (2002).
  • Stein WD, Gulley JL, Schlom J et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin. Cancer Res. 17(4), 907–917 (2011).
  • Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 25(Suppl. 2), B89–B96 (2007).
  • Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res. 13(13), 3776–3782 (2007).
  • Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr. Opin. Immunol. 21(3), 281–285 (2009).
  • deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin. Cancer Res. 18(11), 3022–3029 (2012).
  • Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117(5), 1147–1154 (2007).
  • Godin-Ethier J, Pelletier S, HanafiLAet al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J. Immunol. 183(12), 7752–7760 (2009).
  • Sperner-Unterweger B, Neurauter G, KlieberMet al. Enhanced tryptophan degradation in patients with ovarian carcinoma correlates with several serum soluble immune activation markers. Immunobiology 216(3), 296–301 (2011).
  • Sotiriadou NN, Kallinteris NL, GritzapisADet al. Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors Cancer Immunol. Immunother. 56, 601–613 (2007).
  • Voutsas JF, Gritzapis AD MahairaLG et al. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int. J. Cancer 121, 2031–2041 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.